Slides
Page 1
26 February 2025 1H FY25 Results & Operational Update Revenue stage applied materials technology - Unlocking global battery anode market For personal use only
Page 2
26 February 2025 21H FY25 Results & Operational Update IMPORTANT NOTICE SCOPE & LIMITATIONS This Presentation has been prepared by AnteoTech Ltd (AnteoTech or the Company) (ASX.ADO). The Presentation is a summary only and does not contain all the information about the Company’s assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission. FORWARD LOOKING INFORMATION This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients ofthis Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions. NOT AN OFFER FOR SECURITIES This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and willnot be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into accountyour investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis ofany matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances. UNITED STATES The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company’s securities may not be offered or sold, directly or indirectly, within the United States orto, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the UnitedStates OTHER JURISDICTIONS This Presentation may only be accessed in other jurisdictions where it is legal to do so. THIS RESULTS & OPERATIONAL UPDATE PRESENTATION, IS APPROVED FOR RELEASE BY THE BOARD OF ANTEOTECH LIMITED For personal use only
Page 3
26 February 2025 31H FY25 Results & Operational Update Creating value through the accelerated commercialisation of our societally beneficial solutions. 26 February 2025 31H FY25 Results & Operational Update For personal use only
Page 4
26 February 2025 4 ANTEOTECH AT A GLANCE Platform technology company delivering innovative solutions across the clean energy and life sciences sectors Next-generation high energy battery products – cost & performance Technology Leadership Proprietary platform technology. Strong IP protection. Continuous innovation pipeline Enhancing diagnostic solutions - decreased cost & increased sensitivity Life Sciences Growth Potential Multiple market opportunities. Scalable business model. Strong competitive position Market Opportunity Driven by lithium-ion battery growth Strategic partnerships in place Clear path to market expansion ASX: ADO Focus on revenue growth & market expansion Clean Energy Technology Market Opportunity Addressing rising healthcare demand for rapid diagnostics. Growing Indian health market 1H FY25 Results & Operational Update For personal use only
Page 5
26 February 2025 51H FY25 Results & Operational Update 1HFY25 HIGHLIGHTS Progressing commercialisation activities to drive revenue growth into 2025 and beyond Anteo X & Ultranode validations - Mercedes Benz and other major European car manufacturers – Ultranode achieved 900 cycles at > 70% capacity retention 1 2 3 4 5 $4m Matched Grant Funding & leadership appointments – bolster Clean Energy commercialisation – Fabian Beck commences as Vice President of International Sales –Merrill Gray appointed as a Non-Executive Director US$1.8m Purchase Agreement for AnteoBind with world’s largest vaccine manufacturer – Serum Institute are exploring additional use-cases and expanding use –min. annual order quantity for FY25 met in 1H FY25 Multiple partners progressing in consumer electronics, specialist material and battery manufacturers – Near-term opportunities for both development work and product sales 1H FY25 Product Revenue ↑ 74% pcp - Growing foundations of Product Revenue – Serum Institute of India exceeds minimum annual order in first 6 months –UltranodeTM first commercial order For personal use only
Page 6
26 February 2025 61H FY25 Results & Operational Update 1. As at market close 25 February 2025 2. Total Income includes Product Revenue, Interest Income and the R&D rebate for FY2024 which was received in November 2025. 3. Overhead Reduction excludes non -cash operating costs – D&A of $0.56m (1H24: $0.52m) and Share based expenses of $0.66m (1H24: $0.45m) 4. Grant funding - Queensland Government Critical Minerals and battery Fund grant award. & Australian Renewable Energy Agency. Fun ding available to AnteoTech on terms of grant award FINANCIAL SUMMARY - 1H 25 Growing revenues with a more efficient cost base and multiple near term upside opportunities Cash $7.4m Total Income2 $3.2m Cost base better deployed - increased commercial assets – Ferroglobe claim settled Overhead reduction3 First UltranodeTM revenues (Mercedes-Benz) Serum Institute of India min. orders achieved Growing Revenue Grants Secured4 $3.99m ARENA & $1.4m QLD Govt. grant – funds Gen 1 & 2 UltranodeTM development $5.39m $0.7m vs $0.4 (1H FY24) ARENA & QLD Govt. Debt Nil 74% pcp 25% pcp $4.2m vs $5.6 (1H FY24) Market Cap1 $43m For personal use only
Page 7
26 February 2025 71H FY25 Results & Operational Update Commercial and technical achievements position AnteoTech for near term partnering and revenue opportunities UltranodeTM Commercial Sale Delivered to Mercedes-Benz 900 cycles >70% retention Ultranode 70% silicon anode Clean Energy Life Sciences Corporate 1H 25 - OPERATIONAL ACHIEVEMENTS Annual sales achieved in 6 months1 US$1.8m Agnt with Serum Institute of India New sales targets in India Multiple new partners Vidcare evaluation underway Targeting launch of new diagnostic in 2025 Reduced Costs – Commercial focus New reporting structure & alignment ARENA Grant awarded - $4m Funds Gen. 2 Ultranode development VP International sales Fabian Beck (ex Varta) - based in Germany Production Facility validated Anteo X production ready 1. Min annual sales take or pay orders achieved in 6 months For personal use only
Page 8
26 February 2025 81H FY25 Results & Operational Update UNLOCKING A $21B OPPORTUNITY IN CLEAN ENERGY Next generation battery performance with AnteoTech's technology Rising Demand for Energy Storage Electric Vehicle, storage batteries, consumer electronics and medical devices are driving innovation battery technology. Graphite's Limitations Graphite has reached its energy storage capacity limits, is becoming scarce, and is increasingly expensive. Silicon- Rich Anodes are The Future Increasing silicon content in battery anodes unlocks the next generation of battery performance and storage capabilities. 26 February 2025 81H FY25 Results & Operational Update For personal use only
Page 9
26 February 2025 91H FY25 Results & Operational Update ENABLING AFFORDABLE DIAGNOSTICS Improved workflow, antibody reduction and increased sensitivity. AnteoBind technology Improves test sensitivity and overall performance. Rising Demand for Rapid Diagnostics Growing healthcare needs in human and animal health are driving innovation in point-of- care testing solutions. India Investing in Healthcare Growing healthcare infrastructure and adoption of point-of-care solutions are making critical diagnostics more accessible to underserved populations. For personal use only
Page 10
26 February 2025 1026 February 2025 Monetising the Opportunities 101H FY25 Results & Operational Update For personal use only
Page 11
26 February 2025 111H FY25 Results & Operational Update STRATEGY – MULTIPLE ENTRY POINTS IN ANODE MARKET Diversified sales strategy targeting potential customers across multiple industry verticals 1500 +300 + 500 + 1000 + Power Tools Electric Vehicles Stationary Storage Consumer Electronics AnteoTech’s Commercialisation Opportunities # Full Cell Cycles to 80% capacity 900 @ 70% AnteoTech For personal use only
Page 12
26 February 2025 121H FY25 Results & Operational Update MULTIPLE NEAR - TERM OPPORTUNITIES AnteoTech is targeting revenue across the silicon anode battery market through strategic licensing agreements, contract services, and direct product sales to create a scalable business model. Consumer Electronics (800+ Cycles*) Opportunities 1. Consumer Batteries 1 2. E-Mobility 1 3. E-Mobility 2 4. Medical Device 1 Advanced Chemistries (carbon nano-tube (CNT) & separators) Opportunities 5. Separator Company 1 6. Multi Wall Carbon Nano-Tube 1 7. Single Wall Carbon Nano-Tube 1 Electric Vehicles (1000+ Cycles*) Opportunities 8. EV1 9. EV2 10. EV3 Our opportunities across Silicon Anode Battery Markets Speed to Market Relative market opportunity (estimated) High Low 2 3 1 4 657 9 10 8 Fastest For personal use only
Page 13
26 February 2025 131H FY25 Results & Operational Update CLEAN ENERGY - ONGOING ENGAGEMENT Key targets to build revenue Mercedes-Benz → Support ongoing evaluation of Anteo X and Ultranode → Ultranode agreement– Target 2H25 → Target Anteo X sales for next gen. batteries EV2 & EV3 → Ongoing discussions as they focus on next generation battery developments with high performance and lowest delivered cost per kW/h Electric Vehicles Separator Technology → Confirmation that Anteo X reduces shrinkage > safer batteries → Optimisation of formulation → Target commercial agreement for Anteo X Carbon Nano Tubes → Confirmation Anteo X delivers expected performance improvements → Partner validation then targeting commercial agreement to develop enhanced products with Anteo X Advanced Chemistries Wyon → Leverage recent visit and move to high silicon anode sales. Consumer Battery → Target Commercial agreement in US for mobile phone batteries → Development agreement with niche high performance battery company → Leverage Intl Sales Directors relationships across the industry Consumer & Medical For personal use only
Page 14
26 February 2025 141H FY25 Results & Operational Update LIFE SCIENCES – INDIAN GROWTH OPPORTUNITIES US$1.8m min. Purchase Agreement – 5 years Indian market expansion Evaluation underway → Continue to expand usage in current vaccine program QA → Expand into new vaccine development programs → Expand relationship through assay development services → Explore growth in SII-Lateral flow and other diagnostic tests Building revenue streams for AnteoBind and AnteoBind NXT → Targeted strategy for multiple Indian PoC companies → Rapidly expanding healthcare sector with increasing demand for advanced diagnostic solutions → Leverage Indian government “Health for All” initiatives → Validation of AnteoBind NXT underway with several India companies Business Development Targets – Vidcare → Management meeting planned in India in 2HFY25 → Completing validation of AnteoBind NXT in the initial PoC test for India → Proprietary in-home test for diagnosis of hypothyroidism (or underactive thyroid) For personal use only
Page 15
26 February 2025 151H FY25 Results & Operational Update 1 3 2 4 Delivering multiple revenue streams and agreements - diversification Commercialising high value clean energy customers - validation Building revenues from our key Indian life sciences customers - delivery Effective capital management and strategic partnerships - execution. GOALS FOR SUCCESS IN CY2025 Strategies to build on our commercial momentum – driving revenues and partnerships in CY2025 For personal use only
Page 16
26 February 2025 161H FY25 Results & Operational Update FIVE KEY TAKEAWAYS Two next-generation battery products – compelling data with over 900 charge cycles - Production Facility validated at commercial scale – Technical team in place to support customer requirements 1 Blue chip clean energy partners – Mercedes Benz and Major EV companies - Two evaluations with Mercedes on path to agreement in 2025 – evaluations with other leading companies across the battery sector 2 2025 growing revenues and multiple commercial milestones –period of execution - Agreements - Sales of products – Paid development activities – Partnering opportunities 5 US$1.8m life sciences revenues locked in – world’s largest vaccine manufacturer - Already exceeded minimum annual order in 6 months – additional validation with Vidcare to launch tests across India from 2025 3 $5.4m matched grants secured and Operations overhauled – key commercial leaders appointed - Balance sheet solidified to support 2025 initiatives 4 For personal use only
Page 17
26 February 2025 AnteoTech Proprietary & Confidential 26 February 2025 Thank you. For personal use only